Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus CORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus CORMAX.
ANUSOL HC vs CORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
2.5 mg orally twice daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal: 90% unchanged; minor biliary/fecal: <5%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid